Physician profile

Carol E Miyake

Endocrinology, Diabetes & Metabolism · Poughkeepsie, NY

NPI 1760408330

$3,469.82

in general payments reported to CMS, 2019-2025

33 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $392.17 2019-2022
Glaxosmithkline, LLC. $364.24 2019-2022
Abbvie INC. $357.70 2019-2021
Astrazeneca Pharmaceuticals LP $318.55 2019-2021
Lilly USA, LLC $233.54 2019-2020
Janssen Pharmaceuticals, INC $231.33 2019
Amgen INC. $203.91 2019-2020
Corcept Therapeutics $142.00 2019-2020
Mannkind Corporation $140.49 2019-2021
Pfizer INC. $134.49 2019-2022
Abbott Laboratories $103.81 2019-2021
Mylan Specialty L.P. $77.59 2019-2020
Amneal Pharmaceuticals LLC $77.09 2019-2021
Ibsa Pharma INC. $75.14 2019-2022
Sanofi-Aventis U.S. LLC $64.82 2019
Show all 33 companies

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Carol E Miyake

$3,469.82

in general payments reported 2019-2025

Years
2019-2022
Top company
Novo Nordisk INC

https://glasscript.com/doctor/79193/carol-e-miyake

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.